Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Viguen Movsesian

Psychiatry Pasadena, CA Medical Doctor

NPI 1477548923 CMS profile 112195

100 W California Blvd, Pasadena, CA 91105

Open in the dashboard

General payments

$4,400

163 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Viguen Movsesian of Pasadena, CA is reported in the CMS Open Payments database as having received $4,400 across 163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $693 12
2024 General $112 5
2023 General $411 8
2022 General $1,146 43
2021 General $1,043 49
2020 General $535 23
2019 General $461 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Viguen Movsesian
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Viguen Movsesian were reported at $693. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Viguen Movsesian Psychiatry median Middle half National median
2019 $461 $184 $59–$605 $163
2020 $535 $119 $36–$372 $114
2021 $1,043 $143 $43–$576 $132
2022 $1,146 $153 $50–$590 $149
2023 $411 $170 $56–$651 $160
2024 $112 $179 $57–$673 $164
2025 $693 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $817 38 payments
  2. Teva Pharmaceuticals USA, Inc. $562 8 payments
  3. Alkermes, Inc. $465 24 payments
  4. Otsuka America Pharmaceutical, Inc. $398 21 payments
  5. Janssen Pharmaceuticals, Inc $370 11 payments
  6. AbbVie, Inc. $252 12 payments
  7. Neurocrine Biosciences, Inc. $252 10 payments
  8. Lundbeck LLC $242 9 payments
  9. Allergan Inc. $187 9 payments
  10. ITI, Inc. $125 5 payments
  11. Other $731 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,173 160 payments
  2. Education $228 3 payments
Products named General payments · program years 2019–2025
  1. LATUDA $817 38 payments
  2. ARISTADA INITIO $443 23 payments
  3. ARISTADA Cns $443 23 payments
  4. ARISTADA Cns $443 23 payments
  5. ABILIFY MAINTENA $350 18 payments
  6. ARISTADA Cns $260 15 payments
  7. ARISTADA Cns $260 15 payments
  8. INGREZZA $235 9 payments
  9. VRAYLAR $230 11 payments
  10. UZEDY $228 2 payments
  11. Other $2,813 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,126

Median for Psychiatry: 574

Drug cost

$121,018

Median for Psychiatry: $27,624

Branded share of claims

10.3%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Trinza Paliperidone Palmitate Brand 11 $99,834
Lurasidone Hcl Generic 26 $6,176
Quetiapine Fumarate Generic 178 $3,262
Aripiprazole Generic 62 $2,179
Divalproex Sodium Generic 58 $1,655
Olanzapine Generic 52 $1,236
Gabapentin Generic 63 $670
Divalproex Sodium Er Divalproex Sodium Brand 18 $589
Mirtazapine Generic 71 $508
Bupropion Hcl Sr Bupropion Hcl Brand 60 $481

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$75,327

Medicare's payments for the services billed

Medicare patients

305

Average age 65

Services billed

929

156 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 72%
Arthritis 62%
Diabetes 51%
Ischemic heart disease 42%
Chronic kidney disease 41%
Alzheimer's or dementia 41%
COPD 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $34
$34 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $30
$30 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $24
$24 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $12
$12 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record